Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal
difference between its incidence rate and mortality rate. Advances in oncology over the past …

Circulating tumor DNA (ctDNA) is assumed to reflect tumor burden and has been suggested
as a tool for prognostication and follow‐up in patients with metastatic pancreatic ductal …

Simple Summary Biomarkers for cancer diagnosis, prognosis and prediction are important
tools and an urgent need in precision medicine for pancreatic cancer. In recent years, many …

Reliable biomarkers are required to evaluate and manage pancreatic ductal
adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and …

According to cancer genome sequences, more than 90% of cases of pancreatic ductal
adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables …

Abstract Purpose: Circulating tumor DNA (ctDNA) has emerged as a promising tumor-
specific biomarker in pancreatic cancer, but current evidence of the clinical potential of …

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading
cause of cancer-related mortality within the next decade, with limited effective treatment …